Dr. Reddy’s and Hetero to Launch Affordable HIV Prevention Drug at $40 a Year

and Hetero Labs will roll out generic versions of Lenacapavir, a breakthrough HIV prevention drug, at just $40 a year starting 2027, compared to the US branded price of around $28,000 annually. Lenacapavir, developed by Gilead Sciences and branded as Yeztugo, is a twice-yearly injection that showed nearly 100% effectiveness in large trials. This initiative, supported by Unitaid, Clinton Health Access Initiative, Wits RHI, and the Gates Foundation, is set to make the drug accessible across 120 low- and lower-middle-income countries where the burden is highest. With over 1.3 million new HIV cases annually and 44 million lives lost to date, broader access to affordable generics could significantly reshape prevention efforts. Experts believe long-term demand could exceed 10 million people, making low-cost supply critical to scaling this innovation globally. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.